{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:46:26Z","timestamp":1762004786543},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T00:00:00Z","timestamp":1461888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0437-8","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T01:44:22Z","timestamp":1461894262000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series"],"prefix":"10.1186","volume":"11","author":[{"given":"Dafne Dain Gandelman","family":"Horovitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina X.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Hlavat\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katar\u00edna","family":"Hlavat\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel C.","family":"Tchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneliese","family":"Lopes Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Laercio","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Em\u00edlia Katiane","family":"Embiru\u00e7u de Ara\u00fajo Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Carolina","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra Obikawa","family":"Kyosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Fischinger Moura","family":"De Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,29]]},"reference":[{"issue":"Suppl 5","key":"437_CR1","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2012","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2012;50 Suppl 5:v4\u201312. doi:\n                    10.1093\/rheumatology\/ker394\n                    \n                  .","journal-title":"Rheumatology (Oxford)"},{"key":"437_CR2","volume-title":"The mucopolysaccharidoses. The Metabolic and Molecular Basis of Inherited Disease","author":"E Neufeld","year":"2001","unstructured":"Neufeld E, Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw Hill; 2001."},{"issue":"1","key":"437_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1542\/peds.2008-0416","volume":"123","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123(1):19\u201329. doi:\n                    10.1542\/peds.2008-0416\n                    \n                  .","journal-title":"Pediatrics."},{"key":"437_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1172-3-24","volume":"3","author":"D Moore","year":"2008","unstructured":"Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. 2008;3:24. doi:\n                    10.1186\/1750-1172-3-24\n                    \n                  .","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"437_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1517\/14656566.6.3.489","volume":"6","author":"JE Wraith","year":"2005","unstructured":"Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother. 2005;6(3):489\u2013506. doi:\n                    10.1517\/14656566.6.3.489\n                    \n                  .","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"437_CR6","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120(1):e37\u201346. doi:\n                    10.1542\/peds.2006-2156\n                    \n                  .","journal-title":"Pediatrics"},{"issue":"5","key":"437_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581\u20138. doi:\n                    10.1016\/j.jpeds.2004.01.046\n                    \n                  .","journal-title":"J Pediatr"},{"key":"437_CR8","first-page":"101","volume":"31","author":"T Vertemati","year":"2008","unstructured":"Vertemati T, Micheletti C, Canossa S, Okubo R, Martins A. Impact of ERT on familial life (abstract). J Inherit Metab Dis. 2008;31:101.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"437_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","volume":"96","author":"R Giugliani","year":"2009","unstructured":"Giugliani R, Rojas VM, Martins AM, Valadares ER, Clarke JT, Goes JE, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Molecular Genetics and Metabolism. 2009;96(1):13\u20139. doi:\n                    10.1016\/j.ymgme.2008.10.009\n                    \n                  .","journal-title":"Molecular Genetics and Metabolism"},{"issue":"6","key":"437_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00431-011-1644-x","volume":"171","author":"K D'Aco","year":"2012","unstructured":"D'Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. European Journal of Pediatrics. 2012;171(6):911\u20139. doi:\n                    10.1007\/s00431-011-1644-x\n                    \n                  .","journal-title":"European Journal of Pediatrics"},{"issue":"7","key":"437_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1080\/08035250510031584","volume":"94","author":"S Vijay","year":"2005","unstructured":"Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005;94(7):872\u20137. doi:\n                    10.1080\/08035250510031584\n                    \n                  .","journal-title":"Acta Paediatr"},{"issue":"2","key":"437_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Molecular Genetics and Metabolism. 2014;111(2):63\u201372. doi:\n                    10.1016\/j.ymgme.2013.11.015\n                    \n                  .","journal-title":"Molecular Genetics and Metabolism"},{"issue":"3","key":"437_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","volume":"109","author":"S Laraway","year":"2013","unstructured":"Laraway S, Breen C, Mercer J, Jones S, Wraith JE. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings. Molecular Genetics and Metabolism. 2013;109(3):315\u20136. doi:\n                    10.1016\/j.ymgme.2013.04.023\n                    \n                  .","journal-title":"Molecular Genetics and Metabolism"},{"issue":"1","key":"437_CR14","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1542\/peds.2009-1728","volume":"125","author":"O Gabrielli","year":"2009","unstructured":"Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2009;125(1):e183\u20137. doi:\n                    10.1542\/peds.2009-1728\n                    \n                  .","journal-title":"Pediatrics"},{"issue":"1","key":"437_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","volume":"10","author":"NA Al-Sannaa","year":"2015","unstructured":"Al-Sannaa NA, Bay L, Barbouth DS, Benhayoun Y, Goizet C, Guelbert N, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis. 2015;10(1):131. doi:\n                    10.1186\/s13023-015-0344-4\n                    \n                  .","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"437_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10545-006-0237-8","volume":"29","author":"AT Anbu","year":"2006","unstructured":"Anbu AT, Mercer J, Wraith JE. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis. 2006;29(1):230\u20131. doi:\n                    10.1007\/s10545-006-0237-8\n                    \n                  .","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"437_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229\u201340. doi:\n                    10.1542\/peds.2007-3847\n                    \n                  .","journal-title":"Pediatrics."},{"key":"437_CR18","doi-asserted-by":"publisher","first-page":"CD009354","DOI":"10.1002\/14651858.CD009354.pub2","volume":"9","author":"E Jameson","year":"2013","unstructured":"Jameson E, Jones S, Wraith JE. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. 2013;9:CD009354. doi:\n                    10.1002\/14651858.CD009354.pub2\n                    \n                  .","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"437_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Molecular Genetics and Metabolism. 2007;90(2):171\u201380. doi:\n                    10.1016\/j.ymgme.2006.08.007\n                    \n                  .","journal-title":"Molecular Genetics and Metabolism"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-016-0437-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0437-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T13:01:22Z","timestamp":1581944482000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0437-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,29]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0437-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,29]]},"assertion":[{"value":"13 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"51"}}